NCT04996862

Brief Summary

A survey of health beliefs and cancer screening behaviour and intentions in Hodgkin lymphoma survivors

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
165

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2021

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 26, 2021

Completed
6 days until next milestone

Study Start

First participant enrolled

June 1, 2021

Completed
2 months until next milestone

First Posted

Study publicly available on registry

August 9, 2021

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 28, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 28, 2021

Completed
Last Updated

September 29, 2021

Status Verified

September 1, 2021

Enrollment Period

4 months

First QC Date

May 26, 2021

Last Update Submit

September 28, 2021

Conditions

Hodgkin Lymphoma

Outcome Measures

Primary Outcomes (1)

  • The psychosocial factors predictive of uptake of breast, bowel and lung cancer screening in HL survivors

    Questionnaires

    At baseline visit

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A cohort of Hodgkin lymphoma survivors registered in a clinical follow-up database at The Christie Hospital

You may qualify if:

  • Details held in the ADAPT database at The Christie NHS Foundation trust
  • Aged 18-80
  • Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
  • Treated with radiotherapy and/or alkylating agent containing chemotherapy

You may not qualify if:

  • \* Have previously stated they do not wish to be contacted for research

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Christie NHS Foundation Trust

Manchester, M204BJ, United Kingdom

Location

MeSH Terms

Conditions

Hodgkin Disease

Condition Hierarchy (Ancestors)

LymphomaNeoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 26, 2021

First Posted

August 9, 2021

Study Start

June 1, 2021

Primary Completion

September 28, 2021

Study Completion

September 28, 2021

Last Updated

September 29, 2021

Record last verified: 2021-09

Locations

GB(1)